Federal government makes Carvykti free in public hospitals
Updated
Updated · The Guardian · May 10
Federal government makes Carvykti free in public hospitals
12 articles · Updated · The Guardian · May 10
The multiple myeloma treatment typically costs more than A$200,000 per patient, and the funding decision was announced on Tuesday in Australia.
Researchers called CAR T-cell therapy a potential game-changer because engineered immune cells can deliver lasting protection after a single infusion, though current approved Australian uses remain limited to blood cancers.
Experts said access, domestic manufacturing and research investment are still concerns, while work continues on cheaper next-generation and injectable approaches and on adapting CAR T-cell therapy for solid tumours.
This therapy crushes blood cancer, but can new 'armored' cells finally defeat deadly solid tumors like glioblastoma?
Could a future injection create cancer-fighting cells inside the body, making today's costly therapy obsolete and universally accessible?
As 'living drugs' become potential cures, who decides which patients are worth the half-million-dollar price tag?
Australia’s Free Carvykti Rollout: Transforming Multiple Myeloma Care with Landmark Access and 5-Year Survival Data
Overview
Australia has made a landmark decision to provide Carvykti therapy free of charge in public hospitals for eligible multiple myeloma patients. This move, announced in May 2026, is the result of collaboration between Johnson & Johnson, state governments, and hospitals, ensuring widespread access to this advanced treatment. Multiple myeloma is a serious blood cancer that starts in the bone marrow and, while treatable, remains incurable and can cause severe complications. By making Carvykti widely available, Australia is offering new hope and advanced care options to those battling this challenging disease.